Nov 8, 2026
10x Genomics could benefit from the structural expansion of spatial and single-cell biology, but weak consolidated growth, recurring operating losses, dilution, and an expensive valuation limit its investment appeal.
Sep 14, 2026
MiniMed has a credible diabetes-technology growth engine led by Flex, CGM attachment and a strong pipeline, but negative free cash flow, low current returns and an expensive forward multiple make the post-spin risk-reward unattractive today.
Nov 7, 2026
GRAIL offers substantial long-term growth potential through Galleri's multi-cancer screening technology and pending FDA approval, but weak operating economics, persistent cash burn, dilution, and demanding valuation undermine its current risk-reward profile.